The
global in-vitro toxicity testing market is expected to grow at a CAGR of 6.82%
during the forecast period. The market challenges are hindering the growth,
which includes limitations of preclinical studies, limited number of skilled
professionals, and presence of stringent regulations.
Looking for more
information on this market? Request
a free sample report
The
limitations associated with preclinical studies have made it challenging for
laboratory professionals to adopt in-vitro toxicity testing. For instance,
preclinical studies that use in in-vitro techniques cannot detect rare events,
such as glucose-stimulated insulin secretion, that occur in human beings, as
toxicology studies are based on hazard identification and the subtle effects
noted by patients. This results in greater inaccuracies related to the
detection of toxicology.
The lack of adequate assessment of
risks and the development of risk mitigation strategies related to preclinical
research, including data, documents, and conclusions, will lead to failure of
such preclinical studies and, hence, increase the cost incurred in such
studies. Preclinical studies have practical limitations such as small
experiments, duration of drug administration, which increase the cost of
conducting studies. Hence, the limitation of preclinical studies is affecting
the growth of the market. However, the in-vitro
toxicity testing market is witnessing accelerating growth momentum.
No comments:
Post a Comment